These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 21319202)

  • 41. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity.
    Zollner G; Wagner M; Trauner M
    Pharmacol Ther; 2010 Jun; 126(3):228-43. PubMed ID: 20388526
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nuclear receptor-driven alterations in bile acid and lipid metabolic pathways during gestation.
    Papacleovoulou G; Abu-Hayyeh S; Williamson C
    Biochim Biophys Acta; 2011 Aug; 1812(8):879-87. PubMed ID: 21073948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Common Transcriptional Program of Liver Fibrosis in Mouse Genetic Models and Humans.
    Blagotinšek Cokan K; Urlep Ž; Moškon M; Mraz M; Kong XY; Eskild W; Rozman D; Juvan P; Režen T
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bile acid metabolism and signaling.
    Chiang JY
    Compr Physiol; 2013 Jul; 3(3):1191-212. PubMed ID: 23897684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oxidative stress is bane in chronic liver diseases: Clinical and experimental perspective.
    Ezhilarasan D
    Arab J Gastroenterol; 2018 Jun; 19(2):56-64. PubMed ID: 29853428
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
    Fuchs CD; Traussnigg SA; Trauner M
    Semin Liver Dis; 2016 Feb; 36(1):69-86. PubMed ID: 26870934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells.
    Tanner N; Kubik L; Luckert C; Thomas M; Hofmann U; Zanger UM; Böhmert L; Lampen A; Braeuning A
    Drug Metab Dispos; 2018 Apr; 46(4):326-335. PubMed ID: 29330220
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nuclear receptors. I. Nuclear receptors and bile acid homeostasis.
    Goodwin B; Kliewer SA
    Am J Physiol Gastrointest Liver Physiol; 2002 Jun; 282(6):G926-31. PubMed ID: 12016116
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
    Cariou B
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tisstue culture of adult human liver.
    Demoise CF; Galambos JT; Falek A
    Gastroenterology; 1971 Mar; 60(3):390-9. PubMed ID: 4928810
    [No Abstract]   [Full Text] [Related]  

  • 51. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH.
    Bjursell M; Wedin M; Admyre T; Hermansson M; Böttcher G; Göransson M; Lindén D; Bamberg K; Oscarsson J; Bohlooly-Y M
    PLoS One; 2013; 8(5):e64721. PubMed ID: 23700488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.
    Wu WB; Chen YY; Zhu B; Peng XM; Zhang SW; Zhou ML
    Biochimie; 2015 Aug; 115():86-92. PubMed ID: 26025474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. All-trans-retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade.
    Kim SC; Kim CK; Axe D; Cook A; Lee M; Li T; Smallwood N; Chiang JY; Hardwick JP; Moore DD; Lee YK
    Hepatology; 2014 May; 59(5):1750-60. PubMed ID: 24038081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting nuclear receptors for the treatment of fatty liver disease.
    Tanaka N; Aoyama T; Kimura S; Gonzalez FJ
    Pharmacol Ther; 2017 Nov; 179():142-157. PubMed ID: 28546081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of inflammation in cholestasis: clinical and basic aspects.
    Kosters A; Karpen SJ
    Semin Liver Dis; 2010 May; 30(2):186-94. PubMed ID: 20422500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insufficient bile acid signaling impairs liver repair in CYP27(-/-) mice.
    Meng Z; Liu N; Fu X; Wang X; Wang YD; Chen WD; Zhang L; Forman BM; Huang W
    J Hepatol; 2011 Oct; 55(4):885-95. PubMed ID: 21334403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells.
    Morán-Salvador E; Titos E; Rius B; González-Périz A; García-Alonso V; López-Vicario C; Miquel R; Barak Y; Arroyo V; Clària J
    J Hepatol; 2013 Nov; 59(5):1045-53. PubMed ID: 23831119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
    Xi Y; Li H
    Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
    Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ
    Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.